Destiny Pharma has announced a new clinical programme that is planned to start in China, led by its existing partner China Medical Systems Limited (CMS). Destiny already has an earlier stage (than its two Phase 3-ready programmes) dermal programme on XF-73, but for serious infections of burns and open wounds. This new programme is to be run by CMS for the larger market of the prevention and treatment of superficial bacterial skin infections; and this is the first time that CMS have selected and committed to running an XF programme in China.
27 Sep 2021
New dermal collaboration on XF-73
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
New dermal collaboration on XF-73
Destiny Pharma Plc (DEST:LON) | 14.8 -1 (-31.4%) | Mkt Cap: 14.1m
- Published:
27 Sep 2021 -
Author:
Hannah Crowe | Andy Smith -
Pages:
4
Destiny Pharma has announced a new clinical programme that is planned to start in China, led by its existing partner China Medical Systems Limited (CMS). Destiny already has an earlier stage (than its two Phase 3-ready programmes) dermal programme on XF-73, but for serious infections of burns and open wounds. This new programme is to be run by CMS for the larger market of the prevention and treatment of superficial bacterial skin infections; and this is the first time that CMS have selected and committed to running an XF programme in China.